Results 231 to 240 of about 19,263 (243)

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

New England Journal of Medicine, 2019
Thierry Facon, Shaji K Kumar, Torben Plesner   +2 more
exaly  

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

New England Journal of Medicine, 2016
Antonio Palumbo, Katja C Weisel, Ajay K Nooka   +2 more
exaly  

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

New England Journal of Medicine, 2018
María-Victoria Mateos, Michele Cavo, 鈴木 憲史   +2 more
exaly  

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Lancet, The, 2019
Phillipe Moreau, Michel M Attal, `Cyrille Hulin   +2 more
exaly  

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Lancet, The, 2020
María-Victoria Mateos, Michele Cavo, Joan Bladé   +2 more
exaly  

Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation

New England Journal of Medicine, 2018
Richard M Kaufman, Edwin P Alyea, Jean Marie Connors   +2 more
exaly  

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

New England Journal of Medicine, 2016
Albert Oriol, Hareth Nahi, Jesus San Miguel   +2 more
exaly  

Benefit with daratumumab maintenance

Nature Reviews Clinical Oncology, 2021
exaly  

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

New England Journal of Medicine
Tobias Silzle
exaly  

Improvements with daratumumab

Nature Reviews Clinical Oncology, 2016
Diana Romero
exaly